Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by skyhigh123on May 25, 2018 4:16pm
283 Views
Post# 28082576

Emailed Fred

Emailed Fred Good morning Fred I have one question will the IVIG BLA filing be after the Plasminogen BLA or both at the same time after CMC Controls are implemented. Ric
Fred’s reply 
Hi Ric,

Excellent question. I don't have exact timeline at the moment for IVIG.

As Bruce said during the AGM, all efforts on the plasma derived therapeutics side are focused on the plasminogen BLA file at the moment. We will update on IVIG as soon as possible but I don't have specific timelines to communicate at the moment.

Cheers and have a good weekend Ric.

Best,

Fred

Frederic Dumais
Directeur principal,


Bullboard Posts